@article{APS10434,
author = {Momeneh Ghanaat and Nasser Hashemi Goradel and Arash Arashkia and Nasim Ebrahimi and Sajjad Ghorghanlu and Ziba Veisi Malekshahi and Esmail Fattahi and Babak Negahdari and Hami Kaboosi},
title = {Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer},
journal = {Acta Pharmacologica Sinica},
volume = {42},
number = {12},
year = {2021},
keywords = {},
abstract = {Although most human papillomavirus (HPV) infections are harmless, persistent infection with high-risk types of HPV is known to be the leading cause of cervical cancer. Following the infection of the epithelium and integration into the host genome, the oncogenic proteins E6 and E7 disrupt cell cycle control by inducing p53 and retinoblastoma (Rb) degradation. Despite the FDA approval of prophylactic vaccines, there are still issues with cervical cancer treatment; thus, many therapeutic approaches have been developed to date. Due to strong immunogenicity, a high capacity for packaging foreign DNA, safety, and the ability to infect a myriad of cells, adenoviruses have drawn attention of researchers. Adenovirus vectors have been used for different purposes, including as oncolytic agents to kill cancer cells, carrier for RNA interference to block oncoproteins expression, vaccines for eliciting immune responses, especially in cytotoxic T lymphocytes (CTLs), and gene therapy vehicles for restoring p53 and Rb function.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10434}
}